###begin article-title 0
###xml 25 30 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 39 44 <span type="species:ncbi:9606">Human</span>
Distinct Determinants in HIV-1 Vif and Human APOBEC3 Proteins Are Required for the Suppression of Diverse Host Anti-Viral Proteins
###end article-title 0
###begin p 1
Conceived and designed the experiments: WZ XFY. Performed the experiments: WZ GC. Analyzed the data: WZ AMN RX XFY. Contributed reagents/materials/analysis tools: XFY. Wrote the paper: WZ XFY.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 135 140 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 166 171 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 237 242 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G (A3G) and related cytidine deaminases of the APOBEC3 family of proteins are potent inhibitors of many retroviruses, including HIV-1. Formation of infectious HIV-1 requires the suppression of multiple cytidine deaminases by Vif. HIV-1 Vif suppresses various APOBEC3 proteins through the common mechanism of recruiting the Cullin5-ElonginB-ElonginC E3 ubiquitin ligase to induce target protein polyubiquitination and proteasome-mediated degradation. The domains in Vif and various APOBEC3 proteins required for APOBEC3 recognition and degradation have not been fully characterized.
###end p 3
###begin title 4
Methods and Findings
###end title 4
###begin p 5
###xml 104 109 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 300 305 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 381 386 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 700 705 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In the present study, we have demonstrated that the regions of APOBEC3F (A3F) that are required for its HIV-1-mediated binding and degradation are distinct from those reported for A3G. We found that the C-terminal cytidine deaminase domain (C-CDD) of A3F alone is sufficient for its interaction with HIV-1 Vif and its Vif-mediated degradation. We also observed that the domains of HIV-1 Vif that are uniquely required for its functional interaction with full-length A3F are also required for the degradation of the C-CDD of A3F; in contrast, those Vif domains that are uniquely required for functional interaction with A3G are not required for the degradation of the C-CDD of A3F. Interestingly, the HIV-1 Vif domains required for the degradation of A3F are also required for the degradation of A3C and A3DE. On the other hand, the Vif domains uniquely required for the degradation of A3G are dispensable for the degradation of cytidine deaminases A3C and A3DE.
###end p 5
###begin title 6
Conclusions
###end title 6
###begin p 7
###xml 70 75 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 100 105 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 235 240 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 320 323 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Our data suggest that distinct regions of A3F and A3G are targeted by HIV-1 Vif molecules. However, HIV-1 Vif suppresses A3F, A3C, and A3DE through similar recognition determinants, which are conserved among Vif molecules from diverse HIV-1 strains. Mapping these determinants may be useful for the design of novel anti-HIV inhibitors.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 128 131 128 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Jarmuz1">[1]</xref>
###xml 311 314 311 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Bieniasz1">[2]</xref>
###xml 315 319 315 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-GoilaGaur1">[13]</xref>
###xml 537 541 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Sheehy1">[14]</xref>
###xml 542 546 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Mariani1">[22]</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Esnault1">[23]</xref>
###xml 618 622 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Bogerd1">[24]</xref>
###xml 623 627 623 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Tan1">[31]</xref>
###xml 636 640 636 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Bogerd1">[24]</xref>
###xml 642 646 642 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Hulme1">[25]</xref>
###xml 648 652 648 652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Tan1">[31]</xref>
###xml 654 658 654 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Chiu2">[32]</xref>
###xml 664 668 664 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Turelli2">[33]</xref>
###xml 669 673 669 673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Xu1">[38]</xref>
###xml 683 687 683 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Chen1">[26]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 425 430 <span type="species:ncbi:9606">Human</span>
###xml 525 528 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 533 536 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 660 663 <span type="species:ncbi:10407?0.9699783742526397">HBV</span>
Human cytidine deaminase apolipoprotein B mRNA-editing catalytic polypeptide-like 3G (APOBEC3G, A3G) and other APOBEC3 proteins [1] are related to a family of cytidine deaminases that also includes apolipoprotein B-editing catalytic subunit 1 (APOBEC1), APOBEC2, and activation-induced cytidine deaminase (AID) [2]-[13]. These proteins, which are unique to mammals, have cytidine deaminase activities that modify RNA or DNA. Human APOBEC3 proteins exhibit varying degrees of inhibitory activity against retroviruses, such as HIV and SIV [14]-[22]; endogenous retroviruses [23]; non-LTR retrotransposons, such as LINE1 [24]-[31] and Alu [24], [25], [31], [32]; HBV [33]-[38]; and AAV [26].
###end p 9
###begin p 10
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Luo1">[39]</xref>
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Navarro2">[45]</xref>
###xml 179 183 179 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Wang1">[46]</xref>
###xml 209 213 209 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Svarovskaia1">[47]</xref>
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Khan1">[48]</xref>
###xml 334 338 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu3">[19]</xref>
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Mangeat1">[21]</xref>
###xml 346 350 346 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Mariani1">[22]</xref>
###xml 352 356 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Lecossier1">[49]</xref>
###xml 357 361 357 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Suspene1">[52]</xref>
###xml 483 487 483 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Guo1">[53]</xref>
###xml 488 492 488 492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Guo2">[59]</xref>
###xml 527 531 527 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Schrofelbauer1">[60]</xref>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yang1">[61]</xref>
###xml 638 642 638 642 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Mangeat1">[21]</xref>
###xml 644 648 644 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Mariani1">[22]</xref>
###xml 650 654 650 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Mbisa1">[55]</xref>
###xml 656 660 656 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Luo2">[56]</xref>
###xml 70 75 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 683 688 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In the absence of the Vif protein, APOBEC3 proteins are packaged into HIV-1 particles through an interaction with Gag protein molecules [39]-[45] and the help of cellular 7SL RNA [46] and/or viral genomic RNA [47], [48]. Virion-packaged A3G mediates cytidine deamination in the viral minus-strand DNA during new target cell infection [19], [21], [22], [49]-[52]. Virion-packaged A3G and A3F can also reduce the accumulation of viral DNA by inhibiting reverse transcription processes [53]-[59] or inducing viral DNA degradation [60], [61]. In addition, a potent inhibitory effect of A3G on the formation of proviral DNA has been described [21], [22], [55], [56]. Whether A3G inhibits HIV-1 mainly through cytidine deamination of viral DNA is still controversial.
###end p 10
###begin p 11
###xml 200 204 200 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu4">[62]</xref>
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Kobayashi1">[65]</xref>
###xml 312 316 312 316 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu4">[62]</xref>
###xml 318 322 318 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Mehle1">[63]</xref>
###xml 324 328 324 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Stopak1">[66]</xref>
###xml 329 333 329 333 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Dang1">[72]</xref>
###xml 427 431 427 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu4">[62]</xref>
###xml 432 436 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu5">[64]</xref>
###xml 438 442 438 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Liu2">[71]</xref>
###xml 482 483 482 483 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sub>
###xml 485 490 485 490 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">17&#8211;18</sub>
###xml 492 495 492 495 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3&#8211;5</sub>
###xml 503 507 503 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Luo3">[73]</xref>
###xml 508 512 508 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Xiao2">[76]</xref>
###xml 531 532 531 532 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Stanley1">[77]</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 46 51 <span type="species:ncbi:9606">human</span>
###xml 386 391 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif suppresses the activity of multiple human APOBEC3 proteins by assembling a viral-specific E3 ubiquitin ligase through its interaction with cellular Cullin5 (Cul5)-ElonginB-ElonginC proteins [62]-[65]. Vif induces polyubiquitination of APOBEC3 proteins and tags them for proteasome-mediated degradation [62], [63], [66]-[72]. The carboxyl-terminal BC-box (the SLQxLA motif) of HIV-1 Vif recruits ElonginC and ElonginB [62]-[64], [71], and a highly conserved zinc-binding Hx5Cx17-18Cx3-5H motif [73]-[76] and downstream LPx4L motif in Vif mediate Cul5 association [77].
###end p 11
###begin p 12
###xml 124 128 124 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-GoilaGaur1">[13]</xref>
###xml 130 134 130 134 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Marin1">[67]</xref>
###xml 136 140 136 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Simon1">[78]</xref>
###xml 141 145 141 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-He1">[83]</xref>
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Simon1">[78]</xref>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Russell1">[81]</xref>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Mehle3">[82]</xref>
###xml 381 385 381 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Simon1">[78]</xref>
###xml 386 390 386 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Russell1">[81]</xref>
###xml 392 396 392 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-He1">[83]</xref>
###xml 464 467 464 467 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4&#8211;5</sub>
###xml 473 474 471 472 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 537 541 535 539 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Simon1">[78]</xref>
###xml 542 546 540 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Russell1">[81]</xref>
###xml 548 552 546 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-He1">[83]</xref>
###xml 741 745 739 743 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Dang1">[72]</xref>
###xml 747 751 745 749 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Zhang3">[84]</xref>
###xml 34 39 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 164 169 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 447 452 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 588 593 <span type="species:ncbi:9606">human</span>
###xml 655 660 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 821 826 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Various amino-terminal domains of HIV-1 Vif are responsible for its specificity in recognizing the various APOBEC3 proteins [13], [67], [78]-[83]. For example, the HIV-1 Vif region spanning amino acids 22 to 44 is important for the suppression of A3G but not A3F [78], [81], [82]. In contrast, amino acids 11 to 17 and 74 to 79 are important for the suppression of A3F but not A3G [78]-[81], [83]. A stretch of hydrophobic amino acids 55 to 72 of HIV-1 Vif (VxIPLx4-5LxPhix2YWxL) is critical for both A3G and A3F binding and suppression [78]-[81], [83]. In addition to A3G and A3F, other human cytidine deaminases such as A3C and A3DE are also subject to HIV-1 Vif-induced polyubiquitination and degradation involving Cul5-ElonginB-ElonginC [72], [84]. However, little is known about how these proteins are recognized by HIV-1 Vif.
###end p 12
###begin p 13
###xml 66 71 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In this study, we demonstrate that A3C and A3DE are recognized by HIV-1 Vif in a fashion similar to that observed for A3F, distinct from that seen for A3G. The carboxyl-terminal cytidine deamination domain of A3F alone is sufficient for its interaction with Vif and Vif-mediated degradation of A3F, and the requirements for the degradation of full-length A3F are the same as for its carboxyl-terminal cytidine deamination domain. Thus, the single cytidine deamination domain of A3C and carboxyl-terminal cytidine deamination domain of A3F are sufficient for Vif binding and targeted degradation, in sharp contrast to the requirement for both the amino- and the carboxyl-terminal cytidine deamination domains in the case of A3G.
###end p 13
###begin title 14
Results
###end title 14
###begin title 15
###xml 9 14 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Distinct HIV-1 Vif regions are involved in the suppression of single-domain cytidine deaminase A3C and double-domain A3G
###end title 15
###begin p 16
###xml 81 88 81 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1A</xref>
###xml 310 314 310 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Bishop1">[16]</xref>
###xml 316 320 316 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu2">[18]</xref>
###xml 996 1003 996 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1A</xref>
###xml 20 25 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 115 120 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 171 176 <span type="species:ncbi:9606">human</span>
###xml 286 291 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 352 357 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 460 465 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 581 586 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 640 645 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 878 883 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Distinct regions of HIV-1 Vif have been found to mediate A3G or A3F suppression (Fig. 1A); however, the regions of HIV-1 Vif that are involved in the suppression of other human cytidine deaminases such as A3C have not been determined. Although A3C has been shown to have only weak anti-HIV-1 activity in vitro [16], [18], it is efficiently degraded by HIV-1 Vif through the usage of Cul5-ElonginB-ElonginC E3 ubiquitin ligase. It is possible that A3C has anti-HIV-1 function in vivo that has to be neutralized by Vif to allow viral replication. Alternatively, A3C is recognized by HIV-1 Vif through a similar mechanism as other potent anti-HIV-1 cytidine deaminases such as A3G or A3F. To determine whether the previously identified regions of the Vif protein that are required for A3G or A3F inhibition are also important for its activity against A3C, we generated a series of HIV-1 Vif mutant constructs in which critical residues known to be important for A3G or A3F suppression were mutated (Fig. 1A).
###end p 16
###begin title 17
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of mutations in HIV-1 Vif on Vif function.
###end title 17
###begin p 18
###xml 975 982 941 948 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1B</xref>
###xml 41 46 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 294 299 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 401 404 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 481 486 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 708 713 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 811 814 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 891 896 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Diagram of the functional domains of HIV-1 Vif. The BC-box structure mediates the interaction with ElonginB/C. A zinc-binding domain, Hx2YFxCFx4Phix2APhix7-8Cx5H, is important for Cul5 selection. The N-terminal of Vif has been proposed to bind to APOBEC3 cytidine deaminases. (B) Effect of HIV-1 WT or mutant Vif proteins on the infectivity of SIVagmTanbig up tri, openVif in the presence of A3C. SIV viruses were produced in HEK293T cells co-expressing A3C in the presence of HIV-1 WT or mutant Vif as indicated. Virus infectivity was assessed by Magi assay, with virus infectivity in the presence of WT Vif set to 100%. Error bars represent the standard deviations from triplicate wells. (C) Effect of HIV-1 WT or mutant Vif proteins on the infectivity of NL4-3big up tri, openVif in the presence of A3G. HIV viruses were produced in HEK293T cells co-expressing A3G in the presence of HIV-1 WT or mutant Vif as indicated. Virus infectivity was assessed as described in Fig. 1B.
###end p 18
###begin p 19
###xml 54 58 54 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu2">[18]</xref>
###xml 188 192 188 192 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Zhang4">[85]</xref>
###xml 544 551 514 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1B</xref>
###xml 685 689 655 659 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Zhang4">[85]</xref>
###xml 691 695 661 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Vodicka1">[86]</xref>
###xml 780 787 735 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1B</xref>
###xml 1015 1022 955 962 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1B</xref>
###xml 1137 1141 1077 1081 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Tian1">[79]</xref>
###xml 1143 1147 1083 1087 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Russell1">[81]</xref>
###xml 1217 1224 1157 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1B</xref>
###xml 1349 1356 1289 1296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1B</xref>
###xml 1479 1486 1419 1426 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1C</xref>
###xml 77 106 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
###xml 112 133 <span type="species:ncbi:9534">African green monkeys</span>
###xml 178 183 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 231 236 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
It is well established that A3C is a potent inhibitor [18] of Vif-deificient simian immunodeficiency virus from African green monkeys (SIVagm) and is degraded by both SIVagm and HIV-1 Vif [85]. We therefore examined the ability of HIV-1 Vif and the various Vif mutants to suppress the anti-viral activity of A3C against SIVagmbig up tri, openVif. HEK293T cells were transfected with SIVagmbig up tri, openVif and with an A3C expression vector plus a control vector, an expression vector for wild-type (WT) Vif, or a Vif mutant, as indicated in Fig. 1B. Viruses were produced from the transfected cells, and viral infectivity was tested in a standard Magi assay as previously described [85], [86]. WT Vif suppressed A3C and maintained the infectivity of SIVagmbig up tri, openVif (Fig. 1B, column 2); this level of viral infectivity in the presence of WT Vif was considered to be 100% for comparison purposes. As expected, A3C dramatically reduced the infectivity of SIVagmbig up tri, openVif in the absence of Vif (Fig. 1B, column 1). The Vif DR14/15AA and VifW79A mutants, which have already been reported to be ineffective against A3F [79], [81], were unable to efficiently suppress the anti-viral activity of A3C (Fig. 1B, columns 3 and 6). In contrast, the Vif K22E and VifRH41/42AA mutants were able to suppress the anti-viral activity of A3C (Fig. 1B, columns 4 and 5); as expected, these two mutant proteins were ineffective in suppressing the anti-viral activity of A3G (Fig. 1C, columns 4 and 5).
###end p 19
###begin title 20
###xml 9 14 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Distinct HIV-1 Vif domains are required for A3C degradation and virion exclusion
###end title 20
###begin p 21
###xml 206 213 206 213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2A</xref>
###xml 422 429 422 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1B</xref>
###xml 520 527 520 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2A</xref>
###xml 574 581 574 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2A</xref>
###xml 613 620 613 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2A</xref>
###xml 643 650 643 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2A</xref>
###xml 730 737 730 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2A</xref>
###xml 836 843 836 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2C</xref>
###xml 881 888 881 888 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2C</xref>
###xml 1019 1026 1019 1026 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2A</xref>
###xml 1064 1071 1064 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2C</xref>
###xml 509 514 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We also examined the effect of WT and mutant Vif molecules on the expression and virion exclusion of A3C. For this purpose, we transfected HEK293T cells with an A3C expression vector plus a control vector (Fig. 2A, lane 1), WT Vif-myc expression vector (lane 2), or one of the mutant vectors: VifDR14/15AA (lane 3), VifK22E (lane 4), VifRH41/42AA (lane 5), or VifW79A (lane 6). Consistent with the viral infectivity data (Fig. 1B), the intracellular level of A3C was efficiently reduced in the presence of WT HIV-1 Vif (Fig. 2A, lane 2) when compared to the control vector (Fig. 2A, lane 1). Mutant VifDR14/15AA (Fig. 2A, lane 3) and VifW79A (Fig. 2A, lane 6) were less effective in reducing the stability of A3C than was WT Vif (Fig. 2A, lane 2). Consequently, these two mutants were also less effective in excluding A3C from virions (Fig. 2C, lanes 3 and 6) than was the WT Vif (Fig. 2C, lane 2). Mutant VifK22E and VifRH41/42AA did not produce any significant decrease in the ability of Vif to alter A3C expression (Fig. 2A, lanes 4 and 5) or virion exclusion (Fig. 2C, lanes 4 and 5).
###end p 21
###begin title 22
###xml 23 28 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of mutations in HIV-1 Vif on Vif activity against A3C and A3G.
###end title 22
###begin p 23
###xml 525 532 525 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2A</xref>
###xml 632 635 <span type="species:ncbi:11723?0.9432672590567327">SIV</span>
###xml 1005 1010 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Vif DR14/15 and W79 are required for A3C degradation. HEK293T cells were cotransfected with A3C plus a control vector, WT Vif, or one of the indicated Vif mutant expression vectors. A3C stability was assessed by immunoblotting against A3C-HA, Vif-myc, and ribosomal p19 as a loading control. (B) Vif K22 and RH41/42 are required for A3G degradation. HEK293T cells were cotransfected with A3G plus a control vector, WT Vif, or one of the indicated Vif mutant expression vectors. A3G stability was assessed as described in Fig. 2A. (C) Mutation of Vif DR14/15 and W79 inhibits Vif function, resulting in the packaging of A3C into SIV virions. HEK293T cells were co-transfected with SIVagmTanDeltaVif, A3C plus a control vector, WT Vif, or one of the indicated Vif mutants. Virus was purified from the supernatant and evaluated for A3C packaging by immunoblotting with antibodies against A3C-HA and CAp27. (D) Mutation of Vif K22 and RH41/42 inhibits Vif function, resulting in the packaging of A3G into HIV-1 virions. HEK293T cells were co-transfected with NL4-3DeltaVif and A3G plus a control vector, WT Vif, or one of the indicated Vif mutants. Virus was purified and evaluated by immunoblotting with antibodies against A3G-HA and CAp24.
###end p 23
###begin p 24
###xml 277 284 277 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2B</xref>
###xml 317 324 317 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2D</xref>
###xml 420 427 420 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2B</xref>
###xml 462 469 462 469 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2D</xref>
###xml 526 533 526 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2A</xref>
###xml 557 564 557 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2C</xref>
###xml 60 65 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 358 363 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Collectively, these results indicate that W79 and D14R15 of HIV-1 Vif are important for Vif-mediated degradation of A3C, its exclusion from virions, and the suppression of its anti-viral activity. However, these residues were not important for Vif-mediated degradation of A3G (Fig. 2B) or its exclusion from virions (Fig. 2D). In contrast, K22 and R41H42 of HIV-1 Vif were important for Vif-mediated degradation of A3G (Fig. 2B) and its exclusion from virions, (Fig. 2D) but were dispensable for Vif-mediated A3C degradation (Fig. 2A) and virion exclusion (Fig. 2C).
###end p 24
###begin title 25
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Residues in HIV-1 Vif that are required for A3F binding are also required for A3C binding
###end title 25
###begin p 26
###xml 197 204 197 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3A</xref>
###xml 544 551 544 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3B</xref>
###xml 646 653 646 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3B</xref>
###xml 719 726 719 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3B</xref>
###xml 753 760 753 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3B</xref>
###xml 792 799 792 799 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3B</xref>
###xml 896 903 896 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3A</xref>
###xml 930 937 930 937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3A</xref>
###xml 984 991 984 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3A</xref>
###xml 1258 1265 1258 1265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3B</xref>
###xml 1314 1321 1314 1321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g003">Fig. 3B</xref>
We then evaluated the interaction of WT and mutant Vif molecules with A3C by co-immunoprecipitation analysis. HEK293T cells were transfected with an A3C-HA expression vector plus a control vector (Fig. 3A, lane 1) or an expression vector for WT Vif-myc (lane 2), VifDR14/15AA-myc (lane 3), VifK22E-myc (lane 4), VifRH41/42AA-myc (lane 5), or VifW79A-myc (lane 6). Vif-myc proteins were immunoprecipitated from the cell lysates, and co-precipitation of A3C-HA was detected by immunoblotting. WT Vif-myc efficiently co-immunoprecipitated A3C-HA (Fig. 3B, lane 2); this interaction was specific, since A3C-HA was not detected in the absence of Vif (Fig. 3B, lane 1). Less A3C-HA was co-precipitated with VifDR14/15AA-myc (Fig. 3B, lane 3) and VifW79A-myc (Fig. 3B, lane 6) than with WT Vif-myc (Fig. 3B, lane 2), despite the fact that A3C-HA levels were higher in cells expressing VifDR14/15AA-myc (Fig. 3A, lane 3) and VifW79A-myc (Fig. 3A, lane 6) than in those expressing WT Vif-myc (Fig. 3A, lane 2). These data suggest that the impaired ability of the VifDR14/15AA and VifW79A mutants to degrade and suppress A3C is due at least in part to their reduced interaction with A3C. VifRH41/42AA-myc and VifK22E-myc were able to efficiently interact with A3C-HA (Fig. 3B, lanes 4 and 5), as compared to the WT Vif-myc (Fig. 3B, lane 2).
###end p 26
###begin title 27
###xml 5 7 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 10 12 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">17</sup>
###xml 63 68 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The D14RMR17 and Trp79 domains mediate the interaction between HIV-1 Vif and A3C.
###end title 27
###begin p 28
###xml 147 152 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Vif DR14/15 and W79 showed reduced interaction with A3C when compared to WT Vif. HEK293T cells were cotransfected with A3C and the control vector, HIV-1 Vif, or one of the indicated Vif mutants. At 48 h post-transfection, cell lysates were prepared and immunoprecipitated with anti-myc antibody and agarose-conjugated protein A/G. Cell lysate (A) and the interaction of A3C with WT or mutant Vif molecules(B) were detected by immunoblotting with antibodies against A3G-HA and Vif-myc.
###end p 28
###begin title 29
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Identification of the HIV-1 Vif regions required for A3DE suppression
###end title 29
###begin p 30
###xml 158 165 158 165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4A</xref>
###xml 258 265 258 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4A</xref>
###xml 449 456 449 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4A</xref>
###xml 503 510 503 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4A</xref>
###xml 618 625 618 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4A</xref>
###xml 726 733 726 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4A</xref>
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A3DE also has anti-HIV-1 activity and is neutralized by HIV-1 Vif. We next examined the ability of WT Vif and Vif mutant molecules to affect A3DE expression (Fig. 4A).To this end, we transfected HEK293T with the A3DE expression vector plus a control vector (Fig. 4A, lane 1), the expression vector for WT Vif-myc (lane 2), or one of the Vif mutant molecules (lanes 3, 4, 5, and 6). The intracellular level of A3DE was efficiently reduced by WT Vif (Fig. 4A, lane 2) when compared to the vector control (Fig. 4A, lane 1). As compared to WT Vif, VifDR14/15AA and VifW79A were less effective in reducing A3DE expression (Fig. 4A, lanes 3 and 6). However, VifK22E and VifRH41/42AA preserved the ability to reduce A3DE expression (Fig. 4A, lanes 4 and 5).
###end p 30
###begin title 31
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Effect of mutation of HIV-1 Vif on its activity against A3DE.
###end title 31
###begin p 32
###xml 235 242 235 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2A</xref>
###xml 570 577 566 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g002">Fig. 2D</xref>
###xml 840 847 821 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g001">Fig. 1B</xref>
###xml 125 130 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 343 348 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 682 685 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
(A) Vif DR14/15 and W79 are required for A3DE degradation. HEK293T cells were cotransfected with A3DE plus a control vector, HIV-1 Vif, or one of the indicated Vif mutant expression vectors. A3DE stability was assessed as described in Fig. 2A. (B) Mutation of Vif DR14/15 and W79 inhibits Vif function, resulting in the packaging of A3DE into HIV-1 virions. HEK293T cells were co-transfected with NL4-3DeltaVif and A3DE plus a control vector, WT Vif, or one of the indicated mutant expression vectors. Virus was purified and evaluated for A3DE packaging as described in Fig. 2D. (C) Effect of WT or mutant Vif on the infectivity of NL4-3big up tri, openVif in the presence of A3DE. HIV viruses were produced in HEK293T cells coexpressing A3DE in the presence of WT or mutant Vif as indicated. Virus infectivity was assessed as described in Fig. 1B.
###end p 32
###begin p 33
###xml 39 46 39 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4B</xref>
###xml 92 99 92 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4B</xref>
###xml 256 263 256 263 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4C</xref>
###xml 311 318 311 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4C</xref>
###xml 392 399 392 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4B</xref>
###xml 504 511 504 511 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4C</xref>
###xml 132 137 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 555 560 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 681 686 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
As expected, VifDR14/15AA and VifW79A (Fig. 4B, lanes 3 and 6) were less effective than WT (Fig. 4B, lane 2) in excluding A3DE from HIV-1 virions. Mutant VifDR14/15AA and VifW79A also showed a reduced ability to neutralize the anti-viral activity of A3DE (Fig. 4C, columns 3 and 6) when compared to the WT Vif (Fig. 4C, column 2). Mutant VifK22E and VifRH41/42AA were as effective as WT Vif (Fig. 4B) in excluding A3DE from virions, and they could efficiently counteract the anti-viral activity of A3DE (Fig. 4C). These data indicate that the residues of HIV-1 Vif that are important for A3F and A3C suppression are also important for A3DE suppression. Conversely, the residues of HIV-1 Vif that are important for A3G suppression are dispensable for A3DE suppression.
###end p 33
###begin p 34
###xml 196 203 196 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g005">Fig. 5A</xref>
###xml 562 569 562 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g005">Fig. 5B</xref>
###xml 673 680 673 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g005">Fig. 5B</xref>
###xml 773 780 773 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g005">Fig. 5B</xref>
###xml 803 810 803 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g005">Fig. 5B</xref>
We also evaluated the interaction of WT and Vif mutant molecules with A3DE by co-immunoprecipitation analysis. HEK293T cells were transfected with an A3DE expression vector plus a control vector (Fig. 5A, lane 1) or the expression vector for WT Vif-myc (lane 2), VifDR14/15AA-myc (lane 3), VifK22E-myc (lane 4), VifRH41/42AA-myc (lane 5), or VifW79A-myc (lane 6). The myc-tagged Vif proteins were immunoprecipitated from cell lysates and the co-precipitation of A3DE was assessed by immunoblotting. A3DE-HA was efficiently co-immunoprecipitated with WT Vif-myc (Fig. 5B, lane 2), and this interaction was specific, since A3DE-HA was not precipitated in the absence of Vif (Fig. 5B, lane 1). Even though higher levels of A3DE were detected in cells expressing VifDR14/15AA (Fig. 5B, lane 3) and VifW79A (Fig. 5B, lane 6) than in those expressing WT Vif, significantly less A3DE was immunoprecipitated with VifDR14/15AA and VifW79A than with WT Vif. When intracellular level of A3DE was considered, VifDR14/15AA and VifW79A had 5-10 fold reduced ability to interact with A3DE compared to the WT Vif. Thus, the impaired ability of VifDR14/15AA and VifW79A to degrade A3DE could be attributed, at least in part, to their reduced recognition of A3DE.
###end p 34
###begin title 35
###xml 5 7 5 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">14</sup>
###xml 10 12 10 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">17</sup>
The D14RMR17 and Trp79 domains mediate the interaction between Vif and A3DE.
###end title 35
###begin p 36
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif DR14/15 and W79 all showed reduced interaction with A3DE when compared to WT Vif. HEK293T cells were cotransfected with A3DE and a control vector, WT Vif, or one of the indicated Vif mutants. At 48 h post-transfection, cell lysates were prepared and immunoprecipitated with anti-myc antibody and agarose-conjugated protein A/G. Cell lysates (A) and the interaction of A3C with WT or mutant Vif molecules(B) were detected by immunoblotting with antibodies against A3DE-HA and Vif-myc.
###end p 36
###begin title 37
The carboxyl-terminal deamination domain of A3F behaves like the full-length A3F in terms of Vif sensitivity
###end title 37
###begin p 38
###xml 486 493 486 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g006">Fig. 6A</xref>
###xml 544 551 544 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g006">Fig. 6B</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 103 108 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 264 269 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif utilizes similar regions to interact with A3C, A3DE, and A3F. It is interesting to note that HIV-1 Vif suppresses the single-domain cytidine deaminase A3C and the double-domain enzyme A3F through similar means. This result raises the question of whether HIV-1 Vif recognizes the amino- or carboxyl- terminal domain of A3F. Alignment analysis of A3C and A3F showed that there is a strikingly higher degree of homology (77%) between A3C and the carboxyl-terminal domain of A3F (Fig. 6A) than with the amino-terminal domain of A3F (47%, Fig. 6B).
###end p 38
###begin title 39
The C-CCD of A3F behaves like the full-length A3F.
###end title 39
###begin p 40
###xml 122 127 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 171 176 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 454 459 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 558 563 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Alignment of A3C and the C-CCD of AF. (B) Alignment of A3C and the N-CCD of AF. (C) Interaction of A3F and A3F-C with HIV-1 Vif. HEK293T cells were cotransfected with HIV-1 Vif-myc plus control vector, full-length A3F-HA, or A3F-C-HA. The cells were treated with 10 microM MG132 12 h prior to harvesting., and A3F-HA proteins were immunoprecipitated from cell lysates with an anti-HA antibody conjugated to agarose beads. The interaction of A3F with HIV-1 Vif molecules was detected by immunoblotting with antibodies against A3F-HA and Vif antibody. (D) HIV-1 Vif induces the degradation of the C-CCD of A3F. HEK293T cells were transfected with an expression vector encoding the C-CCD of A3F plus a control vector, WT Vif, or one of the indicated Vif mutant expression vectors. A3F-C stability was assessed by immunoblotting with antibodies against V5, Vif-myc, and beta-tubulin as a loading control.
###end p 40
###begin p 41
###xml 547 554 547 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g006">Fig. 6C</xref>
###xml 688 695 688 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g006">Fig. 6B</xref>
###xml 81 86 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 271 276 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To determine whether the carboxyl-terminal domain of A3F alone can interact with HIV-1 Vif, we constructed an expression vector for the HA epitope-tagged carboxyl-terminal domain of A3F (amino acids 190-373). HEK293T cells were co-transfected with expression vectors for HIV-1 Vif-myc plus a control vector or either full-length A3F-HA or the carboxyl terminal A3F-C-HA. The A3F-HA and A3F-C-HA proteins were immunoprecipitated from transfected cell lysates with anti-HA antibody conjugated to agarose beads. Both full-length A3F-HA and A3F-C-HA (Fig. 6C, lanes 5 and 6) efficiently co-immunoprecipitated Vif-myc. Vif-myc was not co-immunoprecipitated in the absence of any A3F proteins (Fig. 6B, lane 4), indicating the specificity of the assay system.
###end p 41
###begin p 42
###xml 237 244 237 244 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g006">Fig. 6D</xref>
###xml 440 447 440 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g006">Fig. 6D</xref>
###xml 494 501 494 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g006">Fig. 6D</xref>
###xml 604 611 604 611 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g006">Fig. 6D</xref>
###xml 722 729 722 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g006">Fig. 6D</xref>
###xml 68 73 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 133 138 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Since the carboxyl-terminal domain of A3F alone could interact with HIV-1 Vif, we asked whether the A3F-C alone could be degraded by HIV-1 Vif. HEK293T cells were transfected with an expression vector for A3F-C-V5 plus a control vector (Fig. 6D, lane 1), the expression vector for WT Vif-myc (lane 2), or one of various Vif mutants, as indicated (lane 3, 4, 5, and 6). The intracellular level of A3F-C-V5 was efficiently reduced by WT Vif (Fig. 6D, lane 2) when compared to the vector control (Fig. 6D, lane 1). However, VifDR14/15AA and VifW79A showed an impaired ability to reduce A3F-C-V5 expression (Fig. 6D, lanes 3 and 6) when compared to WT Vif. VifK22E and VifRH41/42AA retained their ability to degrade A3F-C-V5 (Fig. 6D, lanes 4 and 5). These data indicate that the requirement for the degradation of full-length A3F is the same as for the degradation of the carboxyl-terminal domain of A3F.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al</italic>
###xml 363 367 363 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Conticello1">[68]</xref>
###xml 458 462 458 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Bogerd2">[87]</xref>
###xml 463 467 463 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Huthoff1">[91]</xref>
###xml 490 496 490 496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al.</italic>
###xml 724 728 724 728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Zhang4">[85]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 150 155 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 353 358 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 432 437 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 594 599 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 670 675 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 799 804 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human APOBEC3 cytidine deaminases are either single-domain or double-domain proteins. Regions in the double-domain A3G protein that are important for HIV-1 Vif-mediated degradation have been shown to span both the amino- and the carboxyl-terminal domains of A3G. Conticello et al. has demonstrated that amino acids 54-124 of A3G alone can interact with HIV-1 Vif [68]. Residues D128 and D130 were later reported to be important for HIV-1 Vif binding as well [87]-[91]. More recently, Zhang et al. have demonstrated that although amino acids 1-156 of A3G are sufficient for the interaction with HIV-1 Vif, additional regions spanning amino acids 105-245 are required for HIV-1 Vif-mediated polyubiquitination and degradation [85]. Thus, the amino-terminal domain of A3G mediates its interaction with HIV-1 Vif, but both cytidine deamination domains of A3G are involved in Vif-mediated degradation.
###end p 44
###begin p 45
###xml 478 482 478 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Liu2">[71]</xref>
###xml 484 488 484 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Tian1">[79]</xref>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Bogerd2">[87]</xref>
###xml 629 633 629 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Schrofelbauer3">[89]</xref>
###xml 710 714 710 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Liu2">[71]</xref>
###xml 823 827 823 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Liu2">[71]</xref>
###xml 1058 1062 1058 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Tian1">[79]</xref>
###xml 162 167 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 468 473 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 614 619 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 692 697 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 756 761 <span type="species:ncbi:9606">human</span>
###xml 799 804 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 961 966 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1048 1053 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We have now found that, unlike the case for A3G, the carboxyl-terminal domain alone of another double-domain protein, A3F, is sufficient for the interaction with HIV-1 Vif, and, more importantly, is all that is required for A3F to undergo Vif-mediated degradation. These new data regarding the degradation of A3F are consistent with our previous observations that the carboxyl- but not the amino-terminal domain of A3F is important for its functional interaction with HIV-1 Vif [71], [79]. Mutation of the aspartate residue, D128, in the amino-terminal domain of A3G has been shown to influence its recognition by HIV-1 Vif [87]-[89]. The analogous residue in A3F, E127, is not important for HIV-1 Vif binding [71], and modifications of this amino acid in human A3F do not change its recognition by HIV-1 Vif or SIVagm Vif [71]. Furthermore, while C-terminal tag modifications of A3F (HA-tag vs V5-tag) can significantly influence its ability to be degraded by HIV-1 Vif, the same modifications of A3G do not affect its ability to be recognized by HIV-1 Vif [79].
###end p 45
###begin p 46
###xml 263 267 263 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-GoilaGaur1">[13]</xref>
###xml 269 273 269 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Marin1">[67]</xref>
###xml 275 279 275 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Simon1">[78]</xref>
###xml 280 284 280 284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-He1">[83]</xref>
###xml 186 191 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 325 330 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 435 440 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 538 543 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 997 1002 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Here we also provide evidence that Vif-mediated degradation of the carboxyl-terminal domain of A3F is similar to that of full-length A3F. We and others have identified unique regions in HIV-1 Vif that are critical for A3G, but not A3F, degradation and vice versa [13], [67], [78]-[83]. For example, W11, D14, R15, and W79 of HIV-1 Vif are required for A3F, but not A3G, binding and degradation. On the other hand, K22, R41, and H42 of HIV-1 Vif are required for A3G but not A3F binding and degradation. Residues such as D14R15 and W79 in HIV-1 Vif that are important for full-length A3F binding and degradation are also important for Vif-mediated degradation of the carboxyl-terminal domain of A3F. On the other hand, residues such as K22 and R41H42 that are important for the Vif-mediated degradation of A3G are dispensable for Vif-mediated degradation of both full-length A3F and the carboxyl-terminal domain of A3F. These data indicate the carboxyl-terminal domain of A3F is the main target of HIV-1 Vif against A3F.
###end p 46
###begin p 47
###xml 751 755 751 755 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Bishop1">[16]</xref>
###xml 757 761 757 761 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu2">[18]</xref>
###xml 56 61 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 263 268 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 334 339 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 736 741 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 787 792 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 998 1003 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1024 1029 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Our data also demonstrate that the N-terminal region of HIV-1 Vif mediates its binding not only to the target molecules A3G and A3F but also to A3C and A3DE. Interestingly, we found that the single-domain cytidine deaminase A3C is also recognized and degraded by HIV-1 Vif through a mechanism similar to that for A3F. The residues in HIV-1 Vif that are important for A3F interaction and degradation were also important for Vif-mediated degradation of A3C. In contrast, those that are mainly important for the Vif-mediated degradation of A3G were found to be dispensable for Vif-mediated degradation of A3C. A3C has a high degree of amino acid homology to the carboxyl-terminal domain of A3F. However, unlike A3F, A3C has only weak anti-HIV-1 function [16], [18]. It is not clear whether HIV-1 Vif has evolved to disable A3F, and its ability to suppress A3C is merely an incidental consequence of the high degree of homology between A3C and the carboxyl-terminal domain of A3F. Whether A3C has anti-HIV-1 activity in certain HIV-1 natural target cells in vivo is an open question.
###end p 47
###begin p 48
###xml 34 38 34 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Dang1">[72]</xref>
###xml 96 102 96 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Fig. 4</xref>
###xml 169 173 169 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Dang1">[72]</xref>
###xml 421 428 421 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g004">Figs. 4</xref>
###xml 433 434 433 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g005">5</xref>
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 308 313 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Consistent with a previous report [72], we found that A3DE has substantial anti-HIV-1 activity (Fig. 4). This protein is expressed in peripheral blood mononuclear cells [72] and macrophages (data not shown). Sequence alignment of A3DE and A3F shows a high degree of homology between these two molecules, and HIV-1 Vif residues required for A3F binding and suppression are also essential for A3DE binding and suppression (Figs. 4 and 5).
###end p 48
###begin p 49
###xml 121 127 121 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g007">Fig. 7</xref>
###xml 234 240 234 240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0003963-g007">Fig. 7</xref>
###xml 248 250 248 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">11</sup>
###xml 256 258 256 258 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">17</sup>
###xml 264 266 264 266 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">74</sup>
###xml 271 273 271 273 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">79</sup>
###xml 805 812 805 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 857 864 857 864 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1063 1067 1063 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Liddament1">[20]</xref>
###xml 97 102 <span type="species:ncbi:9606">human</span>
###xml 130 135 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 284 289 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 349 354 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 417 422 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 594 599 <span type="species:ncbi:9606">human</span>
###xml 706 711 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 799 804 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 880 885 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1036 1041 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1156 1161 <span type="species:ncbi:9606">human</span>
###xml 1176 1181 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1238 1243 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Collectively, our data suggest that Vif employs distinct protein interfaces to recognize various human APOBEC3 proteins (Fig. 7). HIV-1 Vif recognizes A3F, A3C, and A3DE through a similar mechanism that is distinct from that for A3G (Fig. 7). The W11xxDRMR17 and T74GERxW79 motifs of HIV-1 Vif are dispensable for the suppression of the potent anti-HIV-1 cytidine deaminase A3G yet are highly conserved among diverse HIV-1 strains. It is an open question whether these motifs have been conserved only for the suppression of A3F or whether they have been evolutionarily selected to target other human cytidine deaminases, such A3C and A3DE, as well. The highly conserved nature of these residues in diverse HIV-1 Vif molecules indicates that A3F, A3C, and/or A3DE represent a selection force against HIV-1 in vivo. This argument would be consistent with the in vivo observation of HIV-1 G-to-A mutation patterns. GA-to-AA mutations (a pattern generated by A3F, A3C, and/or A3DE) are frequently detected in viral sequences recovered from HIV-1-infected individuals [20]. The highly conserved residues in Vif that are required for the suppression of multiple human cellular anti-HIV-1 factors represent another potential drug target against HIV-1.
###end p 49
###begin title 50
###xml 10 15 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Models of HIV-1 Vif mediated interaction and polyubiquitination of A3G (A) and A3F (B).
###end title 50
###begin p 51
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 261 266 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
(A) Two distinct domains of HIV-1 Vif (G-box and FG-box) mediate interaction with the amino-terminal domain of A3G. However, the carboxyl-terminal domain of A3G is also required for Vif-mediated polyubiquitination and degradation. (B) Three distinct domains of HIV-1 Vif (F1-box, F2-box, and FG-box) mediate interaction with the carboxyl-terminal domain of A3F. The carboxyl-terminal domain of A3F is sufficient for Vif-mediated A3F degradation.
###end p 51
###begin title 52
Materials and Methods
###end title 52
###begin title 53
Plasmid construction
###end title 53
###begin p 54
###xml 330 333 322 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Age</italic>
###xml 346 349 338 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Vif</italic>
###xml 456 460 448 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu4">[62]</xref>
###xml 900 947 892 939 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- GTACGTCGACGCC ATG AACCCGATGGAGGCAATGTATC-3&#8242;</named-content>
###xml 957 1029 949 1021 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- GTACGCGGCCGCTCACGCGTAATCTGGGACGTCGTAAGGGTACTCGAGAATCTCCTGCAGCTTG -3&#8242;</named-content>
###xml 1041 1044 1033 1036 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sal</italic>
###xml 1050 1053 1042 1045 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Not</italic>
###xml 1240 1327 1232 1319 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- GTACGCGGCCGCTCACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACC CTCGAGAATCTCCTGCAGCTTG-3&#8242;</named-content>
###xml 1339 1342 1331 1334 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sal</italic>
###xml 1348 1351 1340 1343 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Not</italic>
The infectious molecular clone of the Vif mutant pNL4-3DeltaVif construct was obtained from the AIDS Research Reagents Program, Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). The SIVagmTanDeltaVif construct was prepared by inserting four nucleotides into the Age site in the Vif coding region of pSIVagmTan-1. VR1012, pHIV-1Vif-myc, pA3G-HA, and pA3F-HA have been previously described [62]. The A3C HA-tagged expression plasmid was a kind gift from Dr Michael Malim (Guy's, King's, and St. Thomas' School of Medicine, King's College, London). A3DE was a generous gift of Dr Y.H. Zheng (Biomedical and Physical Sciences, Michigan State University). Plasmids pVifDR14/15AA, pVifK22E, pVifRH41/42AA, and pVifW79A, were made from pHIV-1Vif-myc by site-directed mutagenesis. A3F-C-HA was amplified with the following primers: forward 5'- GTACGTCGACGCC ATG AACCCGATGGAGGCAATGTATC-3', reverse 5'- GTACGCGGCCGCTCACGCGTAATCTGGGACGTCGTAAGGGTACTCGAGAATCTCCTGCAGCTTG -3' containing SalI and NotI sites, respectively, and a C-terminal HA tag. The PCR product was cloned into VR1012 to generate A3F-C-HA. A3F-C-V5 was constructed with the above forward primer and the reverse primer 5'- GTACGCGGCCGCTCACGTAGAATCGAGACCGAGGAGAGGGTTAGGGATAGGCTTACC CTCGAGAATCTCCTGCAGCTTG-3' containing SalI and NotI sites, respectively, and a C-terminal V5 tag. The PCR product was cloned into VR1012 to generate A3F-C-V5.
###end p 54
###begin title 55
Cell culture, transfection, viral infectivity (MAGI) assays, APOBEC3 degradation, and antibodies
###end title 55
###begin p 56
###xml 129 133 129 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu4">[62]</xref>
###xml 293 297 293 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Yu4">[62]</xref>
###xml 787 791 756 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0003963-Zhang3">[84]</xref>
###xml 882 887 <span type="species:ncbi:9606">human</span>
###xml 997 1002 <span type="species:ncbi:10090">mouse</span>
###xml 1054 1059 <span type="species:ncbi:10090">mouse</span>
HEK293T and MAGI-CCR5 (AIDS Research Reagents Program) cells were maintained and transfected or infected as previously described [62]. Transfection was performed with Lipofectamine2000 (Invitrogen) as instructed by the manufacturer. Viral infectivity (MAGI assays) were performed as described [62]:Virus was produced by transfecting HEK293T cells in a six-well plate with 1 microg of NL4-3big up tri, openVif or SIVagmTanDeltaVif, 1 microg of wild-type or mutant Vif, and 0.3 microg of APOBEC3 as indicated. Virus was harvested from the supernatant for viral infectivity assays, and cell lysates were prepared for immunoblotting. Infectivity was assessed at 48 h post-infection and normalized to the input CAp24 or CAp27. The antibodies used in this study have been previously described [84]: anti-HA antibody, anti-myc antibody, anti-Vif (AIDS Research Reagents Program), and anti-human ribosomal P antigens. The anti-Vif antibody was obtained from the AIDS Research Reagents Program (2221), the mouse anti-V5 antibody from Invitrogen (R96025), and the mouse anti-tubulin antibody from Covance (MMS-410P).
###end p 56
###begin title 57
Immunoprecipitation and immunoblot analysis
###end title 57
###begin p 58
###xml 381 382 367 368 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
A T-25 flask of HEK293T cells was transfected with 3 microg APOBEC3 plus 3 microg of wild-type or mutant Vif expression vectors as indicated. Cells were harvested, washed twice with cold PBS and lysed in lysis buffer (50 mM Tris-HCl [pH 7.5] with 150 mM NaCl, 1% [v/v] Triton X-100, and complete protease inhibitor cocktail tablets) at 4degreesC for 1 h, then centrifuged at 10,000g for 30 min. For myc-tag immunoprecipitation, pre-cleared cell lysates were mixed with anti-myc antibody (Upstate) and incubated with protein G beads at 4degreesC for 3 h. For HA tag immunoprecipitation, pre-cleared cell lysates were mixed with anti-HA antibody-conjugated agarose beads (Roche) and incubated at 4degreesC for 3 h. Samples were then washed three times with washing buffer (20 mM Tris-HCl [pH 7.5], with 100 mM NaCl, 0.1 mM EDTA, and 0.05% [v/v] Tween-20). The beads were eluted with elution buffer (0.1 M glycine-HCl, pH 2.0), and 2x loading buffer was added. The eluted materials were then analyzed by SDS-PAGE and immunoblotting with the anti-myc antibody or the anti-HA antibody as described.
###end p 58
###begin p 59
We thank M. Malim and Y. Zheng for critical reagents and D. McClellan for editorial assistance. The following reagents were obtained through the AIDS Research Reagents Program, Division of AIDS, NIAID, NIH: MAGI-CCR5 cells and the SIVmac251 serum.
###end p 59
###begin title 60
References
###end title 60
###begin article-title 61
An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22.
###end article-title 61
###begin article-title 62
Intrinsic immunity: a front-line defense against viral attack.
###end article-title 62
###begin article-title 63
Retrovirus restriction factors.
###end article-title 63
###begin article-title 64
Retroviral restriction by APOBEC proteins.
###end article-title 64
###begin article-title 65
###xml 21 26 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Recent insights into HIV-1 Vif.
###end article-title 65
###begin article-title 66
APOBEC4, a new member of the AID/APOBEC family of polynucleotide (deoxy)cytidine deaminases predicted by computational analysis.
###end article-title 66
###begin article-title 67
###xml 79 107 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.
###end article-title 67
###begin article-title 68
Editing at the crossroad of innate and adaptive immunity.
###end article-title 68
###begin article-title 69
Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors.
###end article-title 69
###begin article-title 70
Innate cellular defenses of APOBEC3 cytidine deaminases and viral counter-defenses.
###end article-title 70
###begin article-title 71
The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.
###end article-title 71
###begin article-title 72
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 accessory proteins-ensuring viral survival in a hostile environment.
###end article-title 72
###begin article-title 73
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif promotes the formation of high molecular mass APOBEC3G complexes.
###end article-title 73
###begin article-title 74
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
###end article-title 74
###begin article-title 75
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 50 85 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
###end article-title 75
###begin article-title 76
Cytidine deamination of retroviral DNA by diverse APOBEC proteins.
###end article-title 76
###begin article-title 77
###xml 9 14 <span type="species:ncbi:9606">human</span>
###xml 69 74 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 79 84 <span type="species:ncbi:11709?0.8305084745762712">HIV-2</span>
A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins.
###end article-title 77
###begin article-title 78
###xml 47 76 <span type="species:ncbi:11723">simian immunodeficiency virus</span>
APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
###end article-title 78
###begin article-title 79
###xml 83 86 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
###end article-title 79
###begin article-title 80
###xml 76 81 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
###end article-title 80
###begin article-title 81
###xml 32 37 <span type="species:ncbi:9606">human</span>
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
###end article-title 81
###begin article-title 82
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Species-Specific Exclusion of APOBEC3G from HIV-1 Virions by Vif.
###end article-title 82
###begin article-title 83
APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous retroviruses.
###end article-title 83
###begin article-title 84
Cellular inhibitors of long interspersed element 1 and Alu retrotransposition.
###end article-title 84
###begin article-title 85
Selective inhibition of Alu retrotransposition by APOBEC3G.
###end article-title 85
###begin article-title 86
###xml 34 56 <span type="species:ncbi:272636">adeno-associated virus</span>
APOBEC3A is a potent inhibitor of adeno-associated virus and retrotransposons.
###end article-title 86
###begin article-title 87
###xml 25 30 <span type="species:ncbi:9606">human</span>
APOBEC3 proteins inhibit human LINE-1 retrotransposition.
###end article-title 87
###begin article-title 88
APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism.
###end article-title 88
###begin article-title 89
Differential inhibition of long interspersed element 1 by APOBEC3 does not correlate with high-molecular-mass-complex formation or P-body association.
###end article-title 89
###begin article-title 90
Adaptive evolution and antiviral activity of the conserved mammalian cytidine deaminase APOBEC3H.
###end article-title 90
###begin article-title 91
###xml 21 26 <span type="species:ncbi:9606">human</span>
###xml 108 113 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.
###end article-title 91
###begin article-title 92
High-molecular-mass APOBEC3G complexes restrict Alu retrotransposition.
###end article-title 92
###begin article-title 93
Response to Comment on "Inhibition of Hepatitis B Virus Replication by APOBEC3G".
###end article-title 93
###begin article-title 94
###xml 14 31 <span type="species:ncbi:10407">hepatitis B virus</span>
Inhibition of hepatitis B virus replication by APOBEC3G.
###end article-title 94
###begin article-title 95
###xml 26 43 <span type="species:ncbi:10407">hepatitis B virus</span>
Comment on "Inhibition of hepatitis B virus replication by APOBEC3G".
###end article-title 95
###begin article-title 96
###xml 62 67 <span type="species:ncbi:9606">human</span>
###xml 98 115 <span type="species:ncbi:10407">hepatitis B virus</span>
Interferon-inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication.
###end article-title 96
###begin article-title 97
###xml 100 117 <span type="species:ncbi:10407">hepatitis B virus</span>
Cytidine deaminase APOBEC3B interacts with heterogeneous nuclear ribonucleoprotein K and suppresses hepatitis B virus expression.
###end article-title 97
###begin article-title 98
###xml 15 20 <span type="species:ncbi:9606">human</span>
Association of human APOBEC3 cytidine deaminases with the generation of hepatitis virus B x antigen mutants and hepatocellular carcinoma.
###end article-title 98
###begin article-title 99
###xml 29 64 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 94 99 <span type="species:ncbi:9606">human</span>
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging.
###end article-title 99
###begin article-title 100
###xml 28 63 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
APOBEC3G incorporation into human immunodeficiency virus type 1 particles.
###end article-title 100
###begin article-title 101
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G is incorporated into virus-like particles by a direct interaction with HIV-1 Gag nucleocapsid protein.
###end article-title 101
###begin article-title 102
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 and MLV Gag proteins are sufficient to recruit APOBEC3G into virus-like particles.
###end article-title 102
###begin article-title 103
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor.
###end article-title 103
###begin article-title 104
###xml 24 29 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The interaction between HIV-1 Gag and APOBEC3G.
###end article-title 104
###begin article-title 105
Complementary function of the two catalytic domains of APOBEC3G.
###end article-title 105
###begin article-title 106
7SL RNA mediates virion packaging of the antiviral cytidine deaminase APOBEC3G.
###end article-title 106
###begin article-title 107
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 105 110 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
###end article-title 107
###begin article-title 108
###xml 59 94 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes.
###end article-title 108
###begin article-title 109
###xml 17 22 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Hypermutation of HIV-1 DNA in the absence of the Vif protein.
###end article-title 109
###begin article-title 110
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
###end article-title 110
###begin article-title 111
DNA deamination mediates innate immunity to retroviral infection.
###end article-title 111
###begin article-title 112
###xml 84 87 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
###end article-title 112
###begin article-title 113
###xml 54 59 <span type="species:ncbi:9606">Human</span>
###xml 76 81 <span type="species:ncbi:9606">Human</span>
Inhibition of Formula-Primed Reverse Transcription by Human APOBEC3G during Human Immunodeficiency Virus Type 1 Replication.
###end article-title 113
###begin article-title 114
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
###end article-title 114
###begin article-title 115
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration.
###end article-title 115
###begin article-title 116
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
###end article-title 116
###begin article-title 117
###xml 42 77 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Uracil DNA glycosylase is dispensable for human immunodeficiency virus type 1 replication and does not contribute to the antiviral effects of the cytidine deaminase Apobec3G.
###end article-title 117
###begin article-title 118
###xml 45 50 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription.
###end article-title 118
###begin article-title 119
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The interaction of APOBEC3G with HIV-1 nucleocapsid inhibits tRNALys3 annealing to viral RNA.
###end article-title 119
###begin article-title 120
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vpr induces the degradation of the UNG and SMUG uracil-DNA glycosylases.
###end article-title 120
###begin article-title 121
###xml 141 146 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Virion-associated Uracil DNA Glycosylase-2 and Apurinic/Apyrimidinic Endonuclease Are Involved in the Degradation of APOBEC3G-edited Nascent HIV-1 DNA.
###end article-title 121
###begin article-title 122
###xml 59 64 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex.
###end article-title 122
###begin article-title 123
###xml 62 67 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation.
###end article-title 123
###begin article-title 124
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Selective assembly of HIV-1 Vif-Cul5-ElonginB-ElonginC E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines.
###end article-title 124
###begin article-title 125
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Ubiquitination of APOBEC3G by an HIV-1 Vif-Cullin5-Elongin B-Elongin C complex is essential for Vif function.
###end article-title 125
###begin article-title 126
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
###end article-title 126
###begin article-title 127
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
###end article-title 127
###begin article-title 128
###xml 19 22 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
###xml 51 56 <span type="species:ncbi:9606">human</span>
The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G.
###end article-title 128
###begin article-title 129
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
###end article-title 129
###begin article-title 130
###xml 65 100 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
###end article-title 130
###begin article-title 131
###xml 27 62 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase.
###end article-title 131
###begin article-title 132
###xml 70 75 <span type="species:ncbi:9606">human</span>
Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.
###end article-title 132
###begin article-title 133
Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G.
###end article-title 133
###begin article-title 134
A Zinc-binding Region in Vif Binds Cul5 and Determines Cullin Selection.
###end article-title 134
###begin article-title 135
###xml 12 17 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif.
###end article-title 135
###begin article-title 136
###xml 24 27 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G.
###end article-title 136
###begin article-title 137
###xml 28 56 <span type="species:ncbi:12721">human immunodeficiency virus</span>
###xml 86 91 <span type="species:ncbi:9606">human</span>
Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly.
###end article-title 137
###begin article-title 138
###xml 85 90 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification.
###end article-title 138
###begin article-title 139
###xml 54 89 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F.
###end article-title 139
###begin article-title 140
###xml 25 60 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G.
###end article-title 140
###begin article-title 141
###xml 31 66 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 115 120 <span type="species:ncbi:9606">human</span>
Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
###end article-title 141
###begin article-title 142
###xml 46 81 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
###end article-title 142
###begin article-title 143
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
###end article-title 143
###begin article-title 144
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
###end article-title 144
###begin article-title 145
###xml 34 39 <span type="species:ncbi:9606">human</span>
Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation.
###end article-title 145
###begin article-title 146
###xml 57 62 <span type="species:ncbi:9606">human</span>
Indicator cell lines for detection of primary strains of human and simian immunodeficiency viruses.
###end article-title 146
###begin article-title 147
###xml 104 107 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
A single amino acid difference in the host APOBEC3G protein controls the primate species specificity of HIV type 1 virion infectivity factor.
###end article-title 147
###begin article-title 148
A single amino acid determinant governs the species-specific sensitivity of APOBEC3G to Vif action.
###end article-title 148
###begin article-title 149
A single amino acid of APOBEC3G controls its species-specific interaction with virion infectivity factor (Vif).
###end article-title 149
###begin article-title 150
###xml 36 41 <span type="species:ncbi:9606">human</span>
###xml 95 100 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
###end article-title 150
###begin article-title 151
###xml 77 82 <span type="species:ncbi:9606">Human</span>
Identification of Amino Acid Residues in APOBEC3G Required for Regulation by Human Immunodeficiency Virus Type 1 Vif and Virion Encapsidation.
###end article-title 151
###begin p 152
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 152
###begin p 153
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: AI062644 and AI071769
###end p 153

